<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227327</url>
  </required_header>
  <id_info>
    <org_study_id>HERMIONE-7</org_study_id>
    <nct_id>NCT04227327</nct_id>
  </id_info>
  <brief_title>Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)</brief_title>
  <acronym>HERMIONE-7</acronym>
  <official_title>A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) After 1st-line Treatment With High-Dose Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-factor-negative (HER2-) Advanced Breast Cancer Patients. The HERMIONE-7 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milano Bicocca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2-&#xD;
      advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment&#xD;
      for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hormone receptor positive tumors represent the most common form of breast cancer and account&#xD;
      for most of the deaths from the disease. Endocrine therapy (ET) represents the main initial&#xD;
      therapeutic strategy for these patients and has been associated with significant clinical&#xD;
      benefits in the majority of them.&#xD;
&#xD;
      Key-Topics for rationale:&#xD;
&#xD;
        -  Fulvestrant, an Estrogen-Receptor (ER) antagonist with no known agonist effects,&#xD;
           suppresses estrogen signaling by binding to and degrading the ER. Fulvestrant was&#xD;
           approved as a monthly 250 mg dosing regimen based on TTP data demonstrating&#xD;
           non-inferiority versus anastrozole in postmenopausal women whose advanced breast cancer&#xD;
           had progressed during prior anti-estrogen therapy.&#xD;
&#xD;
        -  The international CONFIRM trial compared Fulvestrant 500 mg (High-Dose Fulvestrant&#xD;
           HD-FUL: Fulvestrant 500 mg every month with an additional 500 mg loading dose on Day 14&#xD;
           of the first month) with the monthly 250 mg dose and demonstrated that HD-FUL mg was&#xD;
           associated with improved progression-free survival (PFS) and overall survival (OS) in&#xD;
           postmenopausal women with ER-positive (ER+) advanced breast cancer whose disease had&#xD;
           recurred or progressed after prior endocrine therapy.&#xD;
&#xD;
        -  The FALCON study evaluated the efficacy and safety of HD-FUL in comparison to&#xD;
           anastrozole in HR+, HER2- recurrent or metastatic breast cancer (MBC) patients. Median&#xD;
           duration of PFS with HD-FUL was 16·6 months (95% CI 13·83-20·99) in the whole population&#xD;
           and 22.3 months (95% CI 16·62-32·79) in the non-visceral one. Grade 3 or worse adverse&#xD;
           events were reported by 51 (22%) of 228 patients receiving HD-FUL.&#xD;
&#xD;
        -  Palbociclib, Abemaciclib and Ribociclib + Fulvestrant are superior to Fulvestrant alone&#xD;
           in terms of PFS (PALOMA-3: 9.5 vs 4.6 months; MONARCH-2: 16.4 vs 9.3; MONALEESA-3: 20.5&#xD;
           vs 12.8) in patients who have received prior endocrine therapy for advanced disease or&#xD;
           have relapsed during or within 1 month from adjuvant therapy.&#xD;
&#xD;
        -  A descriptive study analyzed European treatment patterns for HR-positive MBC patients in&#xD;
           real-world clinical practice in the years 2004 - 2013 showed that Fulvestrant was the&#xD;
           initial therapy for advanced disease in 0.8 - 2.6% of the patients. However, the ongoing&#xD;
           real-world GIM-13 AMBRA study showed that in Italy this percentage has grown up to 30%.&#xD;
&#xD;
      At the moment, no data are available regarding the activity of CDK 4/6 inhibitors in patients&#xD;
      treated with HD-FUL as 1st-line therapy, nor are there ongoing trials in this setting.&#xD;
&#xD;
      The aim of this study is to describe the activity of Abemaciclib + aromatase inhibitors (AIs&#xD;
      - letrozole or anastrozole) in HD-FUL pre-treated MBC patients in terms of Clinical Benefit&#xD;
      Rate (CBR).&#xD;
&#xD;
      This is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast&#xD;
      cancer patients who have received HD-FUL as first-line endocrine treatment for their&#xD;
      metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.. Abemaciclib&#xD;
      will be administered orally at 150 mg twice daily until evidence of disease recurrence or&#xD;
      other discontinuation criteria are met, whichever occurs first, together with AIs, as per&#xD;
      specific product instructions. The Simon's optimal two-stage design will be used for the&#xD;
      conduction of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit rate (CBR) in HD-FUL pre-treated MBC patients treated with Abemaciclib + aromatase inhibitors (letrozole or anastrozole)</measure>
    <time_frame>At 6 months from treatment initiation</time_frame>
    <description>CBR is defined as the proportion of patients in Complete Response (CR), Partial Response (PR) or with Stable Disease (SD) &gt;= 24 weeks (as defined by RECIST 1.1 Criteria) evaluated at 6 months from treatment initiation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time To Progression (TTP)</measure>
    <time_frame>Through study completion, an average of 42 months</time_frame>
    <description>TTP is defined as the time from date of start of treatment to the date of event, i.e. the first documented progression or death due to underlying cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Through study completion, an average of 42 months</time_frame>
    <description>ORR is defined as the proportion of patients with best overall response of CR or PR) according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Response (DoOR)</measure>
    <time_frame>Through study completion, an average of 42 months</time_frame>
    <description>DoOR is defined as the time of initial response until documented tumor progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Clinical Benefit (DoCB)</measure>
    <time_frame>Through study completion, an average of 42 months</time_frame>
    <description>DoCB is defined as the time of initial CB until documented tumor progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety profile of Abemaciclib in association with aromatase inhibitors (letrozole or anastrozole)</measure>
    <time_frame>Through study completion, an average of 42 months</time_frame>
    <description>The Medical Dictionary for Regulatory Activities (MedDRA) Version 19.0 (or higher) will be used when reporting AEs by MedDRA terms. The MedDRA Lower Level Term will be used in the treatment-emergent computation. Treatment-emergent adverse events will be summarized by System Organ Class (SOC) and by decreasing frequency of Preferred Term within SOC.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">121</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Abemaciclib + aromatase inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib will be administered at 150 mg twice daily orally + Letrozole 2,5 mg daily or Anastrozole 1 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Abemaciclib will be administered orally at 150 mg twice daily</description>
    <arm_group_label>Abemaciclib + aromatase inhibitors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitors</intervention_name>
    <description>Letrozole 2,5 mg daily or Anastrozole 1 mg daily</description>
    <arm_group_label>Abemaciclib + aromatase inhibitors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female ≥ 18 years of age regardless of menopausal status, who have relapsed while on&#xD;
             prior first-line therapy with HD-FUL&#xD;
&#xD;
          2. Patients with advanced (loco-regionally recurrent, or metastatic) breast cancer not&#xD;
             amenable to curative therapy.&#xD;
&#xD;
          3. Patient has a histological and/or cytological confirmed diagnosis of estrogen-receptor&#xD;
             positive and/or progesterone receptor positive breast cancer by local laboratory.&#xD;
&#xD;
          4. Patient has HER2-negative breast cancer defined as a negative in situ hybridization&#xD;
             test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization&#xD;
             (FISH, CISH, or SISH) test is required by local laboratory testing.&#xD;
&#xD;
          5. WHO performance status of 0-2&#xD;
&#xD;
          6. Measurable disease (according to Response Evaluation Criteria in Solid Tumors&#xD;
             [RECIST], version 1.1) or at least one lytic bone lesion&#xD;
&#xD;
          7. The patient is able to swallow oral medications.&#xD;
&#xD;
          8. The patient has adequate organ function&#xD;
&#xD;
          9. Patient has signed ICF (ICF) obtained before any trial-related activities Patients&#xD;
             must be able to communicate with the investigator and comply with the requirements of&#xD;
             the study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has a known hypersensitivity to any of the excipients of Abemaciclib or&#xD;
             letrozole/anastrozole&#xD;
&#xD;
          2. Patient who received any CDK4/6 inhibitor&#xD;
&#xD;
          3. Patient who received &gt; 1 prior systemic hormonal therapy for advanced breast cancer;&#xD;
             the only admitted previous therapy as 1st-line treatment is HD FUL. Note: Patients who&#xD;
             received ≤ 28 days of letrozole or anastrozole for advanced disease prior to inclusion&#xD;
             in this trial are eligible.&#xD;
&#xD;
          4. Patient who has not had resolution of all acute toxic effects of prior anti-cancer&#xD;
             therapy to NCI CTCAE version 4.03 Grade ≤ 1 (except alopecia or other toxicities not&#xD;
             considered a safety risk for the patient at investigator's discretion)&#xD;
&#xD;
          5. Patient who has received extended-field radiotherapy ≤ 4 weeks or limited field&#xD;
             radiotherapy for palliation ≤ 2 weeks prior to start of treatment, and who has not&#xD;
             recovered to grade 1 or better from related side effects of such therapy (with the&#xD;
             exception of alopecia or other toxicities not considered a safety risk for the patient&#xD;
             at the investigator's discretion).&#xD;
&#xD;
          6. Patients from whom ≥ 25% (Ellis RE 1961) of the bone marrow has been previously&#xD;
             irradiated are also excluded.&#xD;
&#xD;
          7. Patient has a concurrent malignancy or malignancy within 3 years prior to starting&#xD;
             study drug, with the exception of treated, basal or squamous cell carcinoma, non&#xD;
             melanomatous skin cancer or curatively resected cervical cancer.&#xD;
&#xD;
          8. Patient with central nervous system (CNS) metastases unless they meet ALL of the&#xD;
             following criteria:&#xD;
&#xD;
               1. At least 4 weeks from prior therapy for CNS disease completion (including&#xD;
                  radiation and/or surgery) to starting the study treatment&#xD;
&#xD;
               2. Clinically stable CNS lesions at the time of study treatment initiation and not&#xD;
                  receiving steroids and/or enzyme-inducing anti-epileptic medications for the&#xD;
                  management of brain metastases for at least 2 weeks&#xD;
&#xD;
          9. Patient has impairment of gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of the study drugs (e.g., uncontrolled ulcerative&#xD;
             diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small&#xD;
             bowel resection, or preexisting Crohn's disease or ulcerative colitis, or a&#xD;
             preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea)&#xD;
&#xD;
         10. Patient has a known history of HIV infection (testing not mandatory)&#xD;
&#xD;
         11. The patient has serious preexisting medical condition(s) that, in the judgment of the&#xD;
             investigator, would preclude participation in this study (such as severe renal&#xD;
             impairment, [for example, estimated creatinine clearance &lt;30 mL/min], interstitial&#xD;
             lung disease, sever dyspnea at rest or requiring oxygen therapy&#xD;
&#xD;
         12. The patient has a personal history of any of the following conditions: syncope of&#xD;
             cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but&#xD;
             not limited to, ventricular tachycardia and ventricular fibrillation), or sudden&#xD;
             cardiac arrest. Exception: patients with controlled atrial fibrillation for &gt;30 days&#xD;
             prior to randomization are eligible. Any patient with a history of VTE (for example,&#xD;
             DVT of the leg or arm and/or PE) will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marina E Cazzaniga, MD</last_name>
    <phone>+39 0392339037</phone>
    <email>marina.cazzaniga@asst-monza.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica Perez Gila</last_name>
    <phone>+39 0392333683</phone>
    <email>ricercaindipendente.monza@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AOU ospedali riuniti Ancona clinica oncologica</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossana Berardi, MD</last_name>
      <email>R.BERARDI@UNIVPM.IT</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASL di Asti D.H. - oncologia</name>
      <address>
        <city>Asti</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico MR de Conciliis, MD</last_name>
      <email>deconciliis@asl.at.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Oncologico Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Giotta, MD</last_name>
      <email>francescogiotta@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Monsignor Dimiccoli</name>
      <address>
        <city>Barletta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gennaro GADALETA CALDAROLA, MD</last_name>
      <email>gergad@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ULSS 1 Belluno Ospedale San Martino</name>
      <address>
        <city>Belluno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fable Zustovich, MD</last_name>
      <email>fable.zustovich@ulss.belluno.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST degli Spedali civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Pedersini, MD</last_name>
      <email>rebecca.pedersini@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASL AL - Ospedale &quot;Santo Spirito&quot;</name>
      <address>
        <city>Casale Monferrato</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Buosi, MD</last_name>
      <email>rbuosi@aslal.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;SS Annuziata&quot; clinica oncologica</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele De Tursi, MD</last_name>
      <email>detursi@unich.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Lariana</name>
      <address>
        <city>Como</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Giordano, MD</last_name>
      <email>monica.giordano@asst-lariana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Cremona Istituti ospitalieri Cremona</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Generali, MD</last_name>
      <email>daniele.generali@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO S. Croce e Carle Ospedale di Insegnamento</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ornella Garrone, MD</last_name>
      <email>garrone.o@ospedale.cuneo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Monza, Ospedale di Desio</name>
      <address>
        <city>Desio</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Pozzi, MD</last_name>
      <email>paola.pozzi@asst-monza.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ULSS1 Dolomiti - Ospedale di Feltre</name>
      <address>
        <city>Feltre</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davide Pastorelli, MD</last_name>
      <email>davide.pastorelli@aulss1.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Frassoldati, MD</last_name>
      <email>a.frassoldati@ospfe.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera S. Antonio abate</name>
      <address>
        <city>Gallarate</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salvatore Artale, MD</last_name>
      <email>salvatore.artale@asst-valleolona.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AUSL di Reggio Emilia clinica oncologica Guastalla</name>
      <address>
        <city>Guastalla</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Giovanardi, MD</last_name>
      <email>filippo.giovanardi@ausl.re.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera cardinale Giovanni Panico</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiliano Tamburini, MD</last_name>
      <email>emilianotamburini@icloud.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Lecco</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Villa, MD</last_name>
      <email>fe.villa@asst-lecco.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AUSL Toscana Nord Ovest Livorno</name>
      <address>
        <city>Livorno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giacomo Allegrini, MD</last_name>
      <email>GIACOMO.ALLEGRINI@USLNORDOVEST.TOSCANA.IT</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ugo De Giorgi, MD</last_name>
      <email>Ugo.degiorgi@irst.emr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IEO</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabetta Munzone, MD</last_name>
      <email>elisabetta.munzone@ieo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Monza, Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina E Cazzaniga, MD</last_name>
      <email>marina.cazzaniga@asst-monza.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Guarneri, MD</last_name>
      <email>valentina.guarneri@unipd.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale La Maddalena</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Gebbia, MD</last_name>
      <email>vittorio.gebbia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico universitario di Palermo - oncologia medica</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria R Valerio, MD</last_name>
      <email>valerionc17@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisa Ferraris, MD</last_name>
      <email>E.Ferraris@smatteo.pv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaella Palumbo, MD</last_name>
      <email>RAFFAELLA.PALUMBO@ICSMAUGERI.IT</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AUSL di Piacenza Ospedale &quot;Guglielmo da Saliceto&quot;</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Cavanna, MD</last_name>
      <email>L.CAVANNA@AUSL.PC.IT</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriella Moretti, MD</last_name>
      <email>MORETTI.GABRIELLA@ASMN.RE.IT</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Rhodense ospedale di circolo Rho</name>
      <address>
        <city>Rho</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Bollina, MD</last_name>
      <email>robertobollina@netscape.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AUSL Romagna ospedale di Rimini</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gianni, MD</last_name>
      <email>LORENZO.GIANNI@AUSLROMAGNA.IT</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Botticelli, MD</last_name>
      <email>andrea.botticelli@uniroma1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei tumori Regina Elena- oncologia medica A</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Fabi, MD</last_name>
      <email>ALESSANDRA.FABI@VIRGILIO.IT</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei tumori Regina Elena- oncologia medica B</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Vici, MD</last_name>
      <email>PATRIZIA.VICI@IFO.GOV.IT</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale. S. Pertini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Gamucci, MD</last_name>
      <email>teresa.gamucci@aslroma2.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humanitas research hospital</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalba Torrisi, MD</last_name>
      <email>rosalba.torrisi@humanitas.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Ruggi d'Aragona</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clementina Savastano, MD</last_name>
      <email>savastano.clementina@tiscali.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Valle Olona P.O. SARONNO</name>
      <address>
        <city>Saronno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Verusio, MD</last_name>
      <email>CLAUDIO.VERUSIO@ASST-VALLEOLONA.IT</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Airoldi, MD</last_name>
      <email>mairoldi@cittadellasalute.to.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Città della salute e della scienza - Breast Unit</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michela Donadio, MD</last_name>
      <email>MICHELADONADIO@GMAIL.COM</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASL Torino presidio ospedaliero Martini</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Turletti, MD</last_name>
      <email>ANNATURLETTI@VIRGILIO.IT</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APSS provincia autonoma di Trento Ospedale di Trento</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonella Ferro, MD</last_name>
      <email>antonella.ferro@apss.tn.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Settelaghi Varese</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Gallerani, MD</last_name>
      <email>elisa.gallerani@asst-settelaghi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Fiorio, MD</last_name>
      <email>elena.fiorio@aovr.veneto.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>abemaciclib</keyword>
  <keyword>Hormone-Receptor-Positive (HR+)</keyword>
  <keyword>Human-Epidermal-Growth-factor-negative (HER2-)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

